GLENMARK vs SYNCOMF: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. GLENMARK PHARMACEUTICALS shows a higher dividend yield and faster revenue growth, while SYNCOM FORMU (I) shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLENMARK leads 5; SYNCOMF leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLENMARK | SYNCOMF |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLENMARK | SYNCOMF |
|---|---|---|
| Live Price | ₹2,437.2 | ₹20.58 |
| Day Change | -0.89% | -3.65% |
| Volume | 4.13 L | 1.68 Cr |
| 52-Week High | ₹2,537.6 | ₹22.59 |
| 52-Week Low | ₹1,792.6 | ₹10.21 |
| Distance from 52W High | -3.96% | -8.9% |
Valuation
| Metric | GLENMARK | SYNCOMF |
|---|---|---|
| Market Cap | ₹68,490 Cr | ₹1,933 Cr |
| P/E Ratio | 46.23x | 21.38x |
| P/B Ratio | 6.58x | 4.41x |
| EPS | ₹26.07 | ₹0.26 |
| Book Value | ₹372.49 | ₹4.41 |
| Dividend Yield | 0.21% | 0% |
Growth
| Metric | GLENMARK | SYNCOMF |
|---|---|---|
| Revenue Growth (TTM YoY) | 14.3% | -9% |
| EPS Growth (TTM YoY) | 6,575% | 68.8% |
| Qtr Sales Growth | -39.41% | 0.7% |
| Qtr Profit Growth | 52.36% | 1.05% |
Profitability & Leverage
| Metric | GLENMARK | SYNCOMF |
|---|---|---|
| ROE | 12.96% | 18.43% |
| ROCE | 18.25% | 18.63% |
| Net Margin | 8.15% | 15.63% |
| Operating Margin | 12.92% | 20.89% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLENMARK | SYNCOMF |
|---|---|---|
| Promoter Holding | 46.65% | 50.57% |
| FII Holding | 20.89%▲ 0.55 pp | 0.35%▲ 0.14 pp |
| DII Holding | 18.6%▼ 0.69 pp | 0% |
| Public Holding | 13.81%▲ 0.13 pp | 49.08%▼ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLENMARK PHARMACEUTICALS and SYNCOM FORMU (I).
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.